

2-(2-(4-Benzoylpiperazin-1-yl)ethyl)isoindoline-1,3-dione derivatives: Synthesis, docking and acetylcholinesterase inhibitory evaluation as anti-alzheimer agents

Ahmad Mohammadi-Farani ^{1,2}, Nasibeh Abdi ^{3,4}, Alireza Moradi ⁵, Alireza Aliabadi ^{1,4*}

¹ Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran

² Department of Pharmacology, Toxicology and Medical Services, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran

³ Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

⁴ Department of Medicinal Chemistry, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran

⁵ Neurobiomedical Research Center, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran

ARTICLE INFO

Article type:

Original article

Article history:

Received: Jun 5, 2016

Accepted: Jun 30, 2016

Keywords:

Acetylcholinesterase

Alzheimer

Docking

Ellman test

Phthalimide

Synthesis

ABSTRACT

Objective(s): Alzheimer's disease (AD) as progressive cognitive decline and the most common form of dementia is due to degeneration of the cholinergic neurons in the brain. Therefore, administration of the acetylcholinesterase (AChE) inhibitors such as donepezil is the first choice for treatment of the AD. In the present study, we focused on the synthesis and anti-cholinesterase evaluation of new donepezil like analogs.

Materials and Methods: A new series of phthalimide derivatives (compounds 4a-4j) were synthesized via Gabriel protocol and subsequently amidation reaction was performed using various benzoic acid derivatives. Then, the corresponding anti-acetylcholinesterase activity of the prepared derivatives (4a-4j) was assessed by utilization of the Ellman's test and obtained results were compared to donepezil. Besides, docking study was also carried out to explore the likely in silico binding interactions.

Results: According to the obtained results, electron withdrawing groups (Cl, F) at position 3 and an electron donating group (methoxy) at position 4 of the phenyl ring enhanced the acetylcholinesterase inhibitory activity. Compound 4e (m-Fluoro, IC₅₀ = 7.1 nM) and 4i (p-Methoxy, IC₅₀ = 20.3 nM) were the most active compounds in this series and exerted superior potency than donepezil (410 nM). Moreover, a similar binding mode was observed in silico for all ligands in superimposition state with donepezil into the active site of acetylcholinesterase.

Conclusion: Studied compounds could be potential leads for discovery of novel anti-Alzheimer agents in the future.

► Please cite this article as:

Mohammadi-Farani A, Abdi N, Moradi AR, Aliabadi AR. 2-(2-(4-Benzoylpiperazin-1-yl)ethyl)isoindoline-1,3-dione derivatives: Synthesis, docking and acetylcholinesterase inhibitory evaluation as anti-alzheimer agents. Iran J Basic Med Sci 2017; 20:59-66; <http://dx.doi.org/10.22038/ijbms.2017.8095>

Introduction

Alzheimer's disease (AD), discovered by Dr Alois Alzheimer in 1907, is described as a degenerative disease of the central nervous system (CNS) characterized especially by premature senile mental deterioration. AD patients exhibit marked decline in cognitive ability and severe behavioral abnormalities such as irritability, anxiety, depression, disorientation, and restlessness (1). The disease is characterized by the appearance of senile plaques mainly composed of amyloid β (A β), and by the development of neurofibrillary tangles in patients' brain (2). AD is associated with certain neurological changes such as selective loss of cholinergic neurons in the forebrain, extracellular deposition of amyloid peptide, accumulation of intracellular neurofibrillary tangles, and disordered cognitive functions. It was recently reported

that in a significant proportion of AD patients there is also a slowed motor activity and extrapyramidal dysfunction resembling that seen in Parkinson's disease (PD) (3).

Treatment for AD is a daily challenge for physicians and pharmacists. The cognitive symptoms that characterize Alzheimer's disease are thought to be related to the degeneration of cholinergic neurons in the cerebral cortex and subcortical structures. A number of preclinical studies have suggested an association between the cholinergic system and cognition. For example, experimental lesions of the basal forebrain cholinergic system and treatment of animals with muscarinic antagonists produce memory deficits (4, 5). There has been substantial progress in the therapeutic approach to AD in the past few years (Figure 1). Among different strategies investigated to

*Corresponding author: Alireza Aliabadi. Department of Medicinal Chemistry, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran. Tel: +98-831-4276481; Fax: +98-831-4276493; email: aliabadi.alireza@gmail.com




Figure 1. Structures of acetylcholinesterase inhibitors in the market

improve cholinergic neurotransmission, the reduction of ACh hydrolysis by AChE inhibitors is up to date the prevalent effective AD symptomatic treatment (6, 7).

Recently, some (8-10) reports about the efficacy of phthalimide derivatives in inhibition of AChE have been presented (Figure 2). Hence, in the present study, we focused on the design and synthesis of new anti-acetylcholinesterase agents with phthalimide-based structure. In fact, phthalimide based compounds have similar pharmacophoric portions like indanone ring of the donepezil and are able to act as peripheral binding site inhibitor of AChE (8-14).

Materials and Methods

Chemistry

All chemicals consisting starter materials, reagents and solvents were purchased from commercial vendors such as Merck and Sigma-Aldrich. The purity of the synthesized compounds was confirmed by thin layer chromatography (TLC) using various solvents of different polarities. Merck silica gel 60 F₂₅₄ plates were applied for analytical TLC. Column chromatography was performed on Merck silica gel (70-230 mesh) to purify the intermediate and final compounds. ¹H-NMR and ¹³C-NMR spectra were recorded using a Bruker 400 and 250 MHz spectrometers respectively, and chemical shifts are expressed as δ (ppm) with tetramethylsilane (TMS) as internal standard. Intended compounds were dissolved in deuterated chloroform for NMR spectra acquisition. The IR spectra were obtained on a Shimadzu 470 spectrophotometer (potassium bromide disks). Melting points were determined electrothermal melting point analyzer and are uncorrected. The mass spectra were run on a Finigan TSQ-70 spectrometer (Finigan, USA) at 70 eV. Elemental analyses were carried out on a CHNO rapid elemental analyzer (GmbH-Germany) for C, H, N, and O and the results are within $\pm 0.4\%$ of the theoretical values.





Figure 2. Structure of a phthalimide based compound as acetylcholinesterase inhibitor



Scheme 1. Synthetic pathway for preparation of 4a-4j

Synthesis of 2-(2-(Piperazin-1-yl)ethyl)isoindoline-1,3-dione (3)

In a flat bottom flask, equimolar quantities of phthalic anhydride, *N*-amnioethylpiperazine and triethylamine (Et₃N) were mixed in appropriate amount of toluene solvent. The reaction mixture was refluxed for 24 hr and the termination of the reaction and formation of the desired product was confirmed using TLC. The discoloration of the reaction medium and formation of a yellow precipitate was also an indicator of the progress of the reaction. Then, toluene was evaporated under reduced pressure using rotary evaporator apparatus and the obtained yellow viscose and oily residue was washed several times by ethyl acetate (EtOAc) and diethyl ether (Et₂O) (9).

General procedure for synthesis of compounds 4a-4j:

In a flat bottom flask, equimolar quantities of appropriate benzoic acid derivative, *N*-ethyl-*N*-dimethylaminopropyl carbodiimide (EDC) and HOBT were stirred in a acetonitrile solvent for 30 min. Then, equimolar quantity of compound 3 was added and stirring was continued for 24 hr. The product formation was proved using TLC and therefore the end of the reaction was determined. Acetonitrile was evaporated using rotary evaporator apparatus and the residue was dissolved in ethyl acetate/water (50:50). The mixture was moved to the separatory extraction funnel and the aqueous phase was removed. The organic phase was extracted two times by sodium bicarbonate 5% and brine. Anhydrous sodium sulfate was added for drying and then filtered. The ethyl acetate was evaporated under reduced pressure and the obtained oily residue was treated by methanolic HCl to form the hydrochloride salt of the corresponding base for each compound (10, 15-19).

Preliminary design

According to the literature, there is three distinct parts in the structure of donepezil that are necessary for anticholinesterase activity (Figure 3) (1, 12). Namely, phenyl ring of the indanone moiety (part A), nitrogen of the piperidine ring (part B) and phenyl




Figure 3. Design of compounds 4a-4j according to the pharmacophoric necessities of donepezil

ring of the benzyl group (part C) are the critical parts for interacting with the corresponding amino acids in the active site of acetyl cholinesterase enzyme. Phenyl ring of the indanone moiety participates in a π - π stacking interaction with Trp 279. Nitrogen of the piperidine ring is important for creating a cation- π interaction with Phe 330. There is another π - π stacking interaction between phenyl ring of the benzyl moiety of the donepezil and indanone ring of the Trp 84. Hence, according to the pharmacophoric necessities that mentioned above for donepezil interaction, a new series of phthalimide based derivatives were designed (Figure 3).

Docking

The study of molecular docking of all ligands was performed using ArgusLab 4.0 software [20]. All intended ligands were built in arguslab workspace and energy minimization was performed using AM1 as semiempirical method for all ligands. The pdb files of acetyl cholinesterase in complex with donepezil (pdb code: 1EVE) was downloaded from brookhaven protein databank (21, 22). The geometry optimization of the protein structure was optimized geometrically by universal force field (UFF) as a molecular mechanic method. The docking process was done for all ligands in the workspace of ArgusLab software after defining the related groups for each ligand as well as protein. The binding site of donepezil was defined as binding site for searching the best pose and conformation for all ligands. Binding mode and related interactions of ligands with acetyl cholinesterase enzyme were explored in Molegro molecular viewer software (23).

Pharmacology

Ellman test was applied to investigate the capability of the synthesized compounds toward the inhibition of the acetylcholinesterase enzyme. Lyophilized powder of acetylcholinesterase from electric eel source (AChE, E.C. 3.1.1.7, Type V-S, 1000 unit) was purchased from Sigma-Aldrich (Steinheim, Germany). 5,5'-Dithiobis-(2-

nitrobenzoic acid, DTNB), potassium dihydrogen phosphate (KH_2PO_4), dipotassium hydrogen phosphate (K_2HPO_4), potassium hydroxide (KOH), sodium hydrogen carbonate (NaHCO_3), and acetylthiocholine iodide were purchased from Fluka (Buchs, Switzerland). Spectrophotometric measurements were run on a Cecil BioAquarius CE 7250 Double Beam Spectrophotometer.

Compounds **4a-4j** were dissolved in a mixture of 20 ml distilled water and 5 ml methanol and then diluted in 0.1 M $\text{KH}_2\text{PO}_4/\text{K}_2\text{HPO}_4$ buffer (pH 8.0) to yield a final concentration range. According to the literature, the Ellman test was performed for assessment of the anticholinesterase activity of intended compounds *in vitro*. To achieve 20-80% inhibition of AChE activity five different concentrations of each compound were tested. Compounds **4a-4j** were added to the assay solution and preincubated at 25 °C with the enzyme for 15 min followed by adding 0.075 M of acetylthiocholine iodide. After rapid and immediate mixing the change of absorption was measured at 412 nm.

The blank reading contained 3 ml buffer, 200 μl water, 100 μl DTNB and 20 μl substrate. The reaction rates were calculated, and the percent inhibition of test compounds was determined. Each concentration was analyzed in triplicate, and IC_{50} values were determined graphically from inhibition curves (log inhibitor concentration vs percent of inhibition) (24, 25).

Results


Chemistry

All synthesized derivatives were characterized by spectroscopic methods such as $^1\text{H-NMR}$, IR and MS. Melting points were also measured and obtained yields were calculated (Table 1).

2-(2-(Piperazin-1-yl) ethyl) isoindoline-1,3-dione (3)

$^1\text{H NMR}$ (CDCl_3 , 400 MHz) δ (ppm): 2.37 (m, piperazine), 2.54 (m, piperazine), 3.22 (t, phthalimide- CH_2 -piperazine), 3.44 (t, phthalimide- CH_2 - CH_2 -piperazine), 4.73 (NH, piperazine), 7.35-7.85 (m, 4H,

Table 1. Properties of compounds 4a-4j



Compound	(R)	Yield (%)	mp (°C)	MW (g/mol)	Chemical formula
3	-	61	105-109	259	C ₁₄ H ₁₇ N ₃ O ₂
4a	2-Cl	23	229	397	C ₂₁ H ₂₀ N ₃ O ₃ Cl
4b	3-Cl	18	203	397	C ₂₁ H ₂₀ N ₃ O ₃ Cl
4c	4-Cl	15	229	397	C ₂₁ H ₂₀ N ₃ O ₃ Cl
4d	2-F	35	247	381	C ₂₁ H ₂₀ FN ₃ O ₃
4e	3-F	13	243	381	C ₂₁ H ₂₀ FN ₃ O ₃
4f	4-F	52	229	381	C ₂₁ H ₂₀ FN ₃ O ₃
4g	2-OCH ₃	14	211	393	C ₂₃ H ₂₃ N ₃ O ₄
4h	3-OCH ₃	30	127	393	C ₂₃ H ₂₃ N ₃ O ₄
4i	4-OCH ₃	36	127	393	C ₂₃ H ₂₃ N ₃ O ₄
4j	2-NO ₂	49	135	408	C ₂₁ H ₂₃ N ₄ O ₅

phthalimide). ¹³C NMR (DMSO-d₆, 62.5 MHz) δ: 34.8 (Phthalimide-C-C-Piperazine), 36.0 (C_{3,5}-Pyridine), 44.7 (Phthalimide-C-C-Piperazine), 52.8 (C_{2,6}-Pyridine), 123.0 (C_{4,7}-Phthalimide), 130.3 (C_{3a,7a}-Phthalimide), 134.4 (C_{5,6}-Phthalimide), 168.3 (C=O, Phthalimide). IR (KBr, cm⁻¹): 3380 (N-H, Stretch), 3330, 3157 (C-H, Aromatic), 3111 (C-H, Aromatic), 2924 (C-H, Stretch, Asymmetric, Aliphatic), 1730 (C=O, Stretch), 1681, 1521 (N-H, Bending), 1489 (C=C, Aromatic), 1458, 1328, 1303, 1186 (C-N, Stretch), 1143, 1035, 910, 750, 710. MS (*m/z*, %): 259 (M⁺, 10), 224 (30), 174 (30), 160 (60), 149 (85), 99 (100), 70 (70), 57 (65), 41 (40).

2-(2-(4-(2-Chlorobenzoyl) piperazin-1-yl) ethyl) isoindoline-1,3-dione (4a)

¹H NMR (CDCl₃, 400 MHz) δ (ppm): 1.72 (brs, 4H, Piperazine), 2.98 (brs, 4H, Piperazine), 3.42 (m, 2H, Phthalimide-CH₂-CH₂-Piperazine), 4.20 (m, 2H, Phthalimide-CH₂-CH₂-Piperazine), 7.36-7.46 (m, 4H, 2-Chlorophenyl), 7.78 (q, 2H, H_{5,6}-Phthalimide), 7.90 (q, 2H, H_{4,7}-Phthalimide). ¹³C NMR (DMSO-d₆, 62.5 MHz) δ: 32.1 (Phthalimide-C-C-Piperazine), 37.8 (C₃-

Piperazine), 42.8 (C₅-Piperazine), 50.4 (Phthalimide-C-C-Piperazine), 53.2 (C_{2,6}-Piperazine), 123.3 (C_{4,7}-Phthalimide), 126.9 (C₅-2-Chlorophenyl), 127.2 (C₆-4-Chlorophenyl), 127.8 (C₄-2-Chlorophenyl), 129.2 (C₃-2-Chlorophenyl), 129.6 (C₁-2-Chlorophenyl), 131.1 (C_{3a,7a}-Phthalimide), 132.1 (C_{5,6}-Phthalimide), 134.5 (C₂-2-Chlorophenyl), 165.7 (C=O, Phthalimide), 168.0 (C=O, 2-Chlorobenzoyl). IR (KBr, cm⁻¹): 3095 (C-H, Stretch, Aromatic), 2924 (C-H, Stretch, Asymmetric, Aliphatic), 2858 (C-H, Stretch, Symmetric, Aliphatic), 1712 (C=O, Stretch, Phthalimide), 1639 (C=O, Stretch, Amide), 1465, 1246 (C-N, Stretch).

2-(2-(4-(3-Chlorobenzoyl) piperazin-1-yl) ethyl) isoindoline-1,3-dione (4b)

¹H NMR (CDCl₃, 400 MHz) δ (ppm): 2.91 (brs, 4H, Piperazine), 3.41 (brs, 4H, Piperazine), 3.88 (m, 4H, Phthalimide-CH₂-CH₂-Piperazine), 7.43-7.49 (m, 4H, 3-Chlorophenyl), 7.78 (q, 2H, H_{5,6}-Phthalimide), 7.91 (q, 2H, H_{4,7}-Phthalimide). ¹³C NMR (DMSO-d₆, 62.5 MHz) δ: 35.8 (Phthalimide-C-C-Piperazine), 54.2 (C₃-Piperazine), 45.9 (C₅-Piperazine), 52.7 (Phthalimide-C-C-Piperazine), 55.3 (C_{2,6}-Piperazine), 124.6 (C_{4,7}-Phthalimide), 127.1 (C₆-3-Chlorophenyl), 129.7 (C₅-3-Chlorophenyl), 131.8 (C₂-3-Chlorophenyl), 133.1 (C₄-3-Chlorophenyl), 134.9 (C₃-3-Chlorophenyl), 135.2 (C_{5,6}-Phthalimide), 136.9 (C₁-3-Chlorophenyl), 166.2 (C=O, Phthalimide), 169.5 (C=O, 3-Chlorobenzoyl). IR (KBr, cm⁻¹): 3066 (C-H, Stretch, Aromatic), 2924 (C-H, Stretch, Asymmetric, Aliphatic), 2854 (C-H, Stretch, Symmetric, Aliphatic), 1712 (C=O, Stretch, Phthalimide), 1631 (C=O, Stretch, Amide), 1249 (C-N, Stretch).

2-(2-(4-(4-Chlorobenzoyl) piperazin-1-yl) ethyl) isoindoline-1,3-dione (4c)

¹H NMR (CDCl₃, 400 MHz) δ (ppm): 1.78 (brs, 4H, Piperazine), 2.91 (brs, 4H, Piperazine), 3.42 (m, 2H, Phthalimide-CH₂-CH₂-Piperazine), 4.20 (m, 2H, Phthalimide-CH₂-CH₂-Piperazine), 7.43 (m, 4H, 4-Chlorophenyl), 7.78 (q, 2H, H_{5,6}-Phthalimide), 7.89 (q, 2H, H_{4,7}-Phthalimide). ¹³C NMR (DMSO-d₆, 62.5 MHz) δ: 32.0 (Phthalimide-C-C-Piperazine), 37.3 (C₃-Piperazine), 38.03 (C₅-Piperazine), 50.4 (Phthalimide-C-C-Piperazine), 53.1 (C_{2,6}-Piperazine), 123.1 (C_{4,7}-Phthalimide), 128.3 (C_{3,5}-4-Chlorophenyl), 128.6 (C_{2,6}-4-Chlorophenyl), 129.2 (C₁-4-Chlorophenyl), 131.9 (C_{3a,7a}-Phthalimide), 133.5 (C_{5,6}-Phthalimide), 134.4 (C₄-4-Chlorophenyl), 167.9 (C=O, Phthalimide), 168.1 (C=O, 4-Chlorobenzoyl). IR (KBr, cm⁻¹): 3097 (C-H, Stretch, Aromatic), 2962 (C-H, Stretch, Asymmetric, Aliphatic), 2924 (C-H, Stretch, Symmetric, Aliphatic), 1712 (C=O, Stretch, Phthalimide), 1635 (C=O, Stretch, Amide), 1288 (C-N, Stretch).

2-(2-(4-(2-Fluorobenzoyl) piperazin-1-yl) ethyl) isoindoline-1,3-dione (4d)

¹H NMR (CDCl₃, 400 MHz) δ (ppm): 2.98 (brs, 4H, Piperazine), 3.46 (brs, 4H, Piperazine), 3.69-4.21 (m, 4H, Phthalimide-CH₂-CH₂-Piperazine), 7.12-7.55 (m, 4H, 2-Fluorophenyl), 7.77 (q, 2H, H_{5,6}-Phthalimide), 7.88 (q, 2H, H_{4,7}-Phthalimide). ¹³C NMR (DMSO-d₆, 62.5 MHz) δ: 34.6 (Phthalimide-C-C-Piperazine), 42.2 (C₃-Piperazine), 41.1 (C₅-Piperazine), 50.9 (Phthalimide-C-C-Piperazine), 53.6 (C_{2,6}-Piperazine), 116.2 (d, C₃-2-Fluorophenyl), 120.2 (d, C₁-2-Fluorophenyl), 123.8 (C_{4,7}-Phthalimide), 125.6 (C₅-2-Fluorophenyl), 127.5 (C₆-2-Fluorophenyl), 130.6 (C_{3a,7a}-Phthalimide), 132.1 (C₄-2-Fluorophenyl), 136.1 (C_{5,6}-Phthalimide), 161.1 (d, C₂-2-Fluorophenyl), 166.2 (d, C=O, 2-Fluorobenzoyl), 167.3 (C=O, Phthalimide). IR (KBr, cm⁻¹) $\bar{\nu}$: 3132 (C-H, Stretch, Aromatic), 2954 (C-H, Stretch, Asymmetric, Aliphatic), 2927 (C-H, Stretch, Symmetric, Aliphatic), 1712 (C=O, Stretch, Phthalimide), 1650 (C=O, Stretch, Amide), 1608 (C=C, Stretch, Aromatic), 1470, 1253 (C-N, Stretch). MS (*m/z*, %): 381 (M⁺, 5), 221 (100), 166 (10), 123 (50), 95 (10), 75 (3), 56 (3).

2-(2-(4-(3-Fluorobenzoyl) piperazin-1-yl) ethyl) isoindoline-1,3-dione (4e)

¹H NMR (CDCl₃, 400 MHz) δ (ppm): 2.91 (brs, 4H, Piperazine), 3.44 (brs, 4H, Piperazine), 3.63-4.21 (m, 4H, Phthalimide-CH₂-CH₂-Piperazine), 7.22 (m, 2H, H_{5,6}-3-Fluorophenyl), 7.45 (m, 1H, H₄-3-Fluorophenyl), 7.73 (m, 1H, H₂-3-Fluorophenyl), 7.77 (q, 2H, H_{5,6}-Phthalimide), 7.89 (q, 2H, H_{4,7}-Phthalimide). ¹³C NMR (DMSO-d₆, 62.5 MHz) δ: 37.3 (Phthalimide-C-C-Piperazine), 44.6 (C₃-Piperazine), 45.5 (C₅-Piperazine), 53.1 (Phthalimide-C-C-Piperazine), 55.6 (C_{2,6}-Piperazine), 114.5 (d, C₂-3-Fluorophenyl), 119.2 (d, C₄-3-Fluorophenyl), 122.4 (C_{4,7}-Phthalimide), 125.2 (C₆-3-Fluorophenyl), 130.5 (d, C₅-3-Fluorophenyl), 132.6 (C_{3a,7a}-3-Fluorophenyl), 133.3 (d, C₁-3-Fluorophenyl), 136.4 (C_{5,6}-Phthalimide), 159.2 (C₃-3-Fluorophenyl), 167.2 (C=O, Phthalimide), 168.4 (d, C₁-2-Fluorophenyl).

2-(2-(4-(4-Fluorobenzoyl) piperazin-1-yl) ethyl) isoindoline-1,3-dione (4f)

¹H NMR (CDCl₃, 400 MHz) δ (ppm): 2.07 (brs, 4H, Piperazine), 2.96 (brs, 4H, Piperazine), 3.44-4.20 (m, 4H, Phthalimide-CH₂-CH₂-Piperazine), 7.15 (m, 2H, 4-Fluorophenyl), 7.49 (m, 2H, 4-Fluorophenyl), 7.77 (q, 2H, H_{5,6}-Phthalimide), 7.88 (q, 2H, H_{4,7}-Phthalimide). ¹³C NMR (DMSO-d₆, 62.5 MHz) δ: 32.0 (Phthalimide-C-C-Piperazine), 50.6 (Phthalimide-C-C-Piperazine), 53.1 (C_{2,6}-Piperazine), 115.5 (d, C_{3,5}-4-Fluorophenyl), 123.1 (C_{4,7}-4-Fluorophenyl), 129.8 (d, C_{2,6}-4-Fluorophenyl), 131.1 (C_{3a,7a}-Phthalimide), 132.0 (C₁-4-Fluorobenzoyl), 134.3 (C_{5,6}-Phthalimide), 162.8 (d, C₄-4-Fluorophenyl), 167.9 (C=O, Phthalimide), 168.2 (C=O, 4-Fluorobenzoyl). IR (KBr, cm⁻¹) $\bar{\nu}$: 3062 (C-H, Stretch, Aromatic), 2924 (C-H, Stretch, Asymmetric,

Aliphatic), 2870 (C-H, Stretch, Symmetric, Aliphatic), 1712 (C=O, Stretch, Phthalimide), 1635 (C=O, Stretch, Amide), 1470, 1284 (C-N, Stretch). MS (*m/z*, %): 381 (M⁺, 3), 242 (8), 221 (100), 174 (8), 166 (10), 123 (70), 99 (10), 95 (15), 75 (5), 56 (5).

2-(2-(4-(2-Methoxybenzoyl) piperazin-1-yl) ethyl) isoindoline-1,3-dione (4g)

¹H NMR (CDCl₃, 400 MHz) δ (ppm): 1.44 (brs, 4H, Piperazine), 3.14 (brs, 4H, Piperazine), 3.49-4.21 (m, 4H, Phthalimide-CH₂-CH₂-Piperazine), 6.81-7.49 (m, 4H, 2-Methoxyphenyl), 7.76 (q, 2H, H_{5,6}-Phthalimide), 7.87 (q, 2H, H_{4,7}-Phthalimide). ¹³C NMR (DMSO-d₆, 62.5 MHz) δ: 20.7 (Phthalimide-C-C-Piperazine), 30.3 (C₃-Piperazine), 43.9 (C₅-Piperazine), 54.4 (C_{2,6}-Piperazine), 56.5 (Phthalimide-C-C-Piperazine), 58.3 (-OCH₃), 105 (C₆-2-Methoxyphenyl), 113.3 (C₄-2-Methoxyphenyl), 120.2 (C_{4,7}-Phthalimide), 124.4 (C₂-2-Methoxyphenyl), 131.4 (C₅-2-Methoxyphenyl), 132.6 (C_{3a,7a}-Phthalimide), 135.9 (C_{5,6}-Phthalimide), 137.6 (C₁-2-Methoxyphenyl), 160.2 (C₃-2-Methoxyphenyl), 169.9 (C=O, Phthalimide), 171.1 (C=O, 3-Methoxybenzoyl). MS (*m/z*, %): 393 (10), 242 (5), 233 (100), 217 (15), 174 (3), 160 (3), 135 (75), 77 (10).

2-(2-(4-(3-Methoxybenzoyl) piperazin-1-yl) ethyl) isoindoline-1,3-dione (4h)

¹H NMR (CDCl₃, 400 MHz) δ (ppm): 2.01 (brs, 4H, Piperazine), 2.98 (brs, 4H, Piperazine), 3.37-4.24 (m, 4H, Phthalimide-CH₂-CH₂-Piperazine), 7.03 (m, 2H, 3-Methoxyphenyl), 7.36 (m, 1H, 3-Methoxyphenyl), 7.64 (m, 1H, 3-Methoxyphenyl), 7.76 (q, 2H, H_{5,6}-Phthalimide), 7.88 (q, 2H, H_{4,7}-Phthalimide). ¹³C NMR (DMSO-d₆, 62.5 MHz) δ: 36.1 (Phthalimide-C-C-Piperazine), 43.2 (C₃-Piperazine), 45.6 (C₅-Piperazine), 53.4 (Phthalimide-C-C-Piperazine), 54.8 (C_{2,6}-Piperazine), 56.6 (-OCH₃), 118.1 (C₆-3-Methoxyphenyl), 120.4 (C₄-3-Methoxyphenyl), 123.7 (C_{4,7}-Phthalimide), 124.7 (C₂-3-Methoxyphenyl), 125.3 (C₅-3-Methoxyphenyl), 131.6 (C_{3a,4a}-Phthalimide), 134.8 (C_{5,6}-Phthalimide), 135.0 (C₁-3-Methoxyphenyl), 159.7 (C₃-3-Methoxyphenyl), 166.5 (C=O, Phthalimide), 169.3 (C=O, 3-Methoxybenzoyl). IR (KBr, cm⁻¹) $\bar{\nu}$: 3070 (C-H, Stretch, Aromatic), 2924 (C-H, Stretch, Asymmetric, Aliphatic), 2825 (C-H, Stretch, Symmetric, Aliphatic), 1712 (C=O, Stretch, Phthalimide), 1639 (C=O, Stretch, Amide), 1462, 1242 (C-N, Stretch). MS (*m/z*, %): 393 (M⁺, 3), 242 (12), 233 (100), 217 (12), 174 (10), 135 (70), 99 (15), 77 (15).

2-(2-(4-(4-Methoxybenzoyl) piperazin-1-yl) ethyl) isoindoline-1,3-dione (4i)

¹H NMR (CDCl₃, 400 MHz) δ (ppm): 2.81 (brs, 4H, Piperazine), 3.00 (brs, 4H, Piperazine), 3.46-4.18 (m, 4H, Phthalimide-CH₂-CH₂-Piperazine), 7.03 (m, 2H, 3-Methoxyphenyl), 7.41-7.67 (m, 4H, 4-Methoxyphenyl), 7.76 (m, 2H, H_{5,6}-Phthalimide), 7.88 (m, 2H, H_{4,7}-

Phthalimide). ^{13}C NMR (DMSO- d_6 , 62.5 MHz) δ : 35.8 (Phthalimide-C-C-Piperazine), 44.3 (C₃-Piperazine), 47.4




Figure 4. Structure of compound **4e** (3-fluoro derivative) in the active site of acetylcholinesterase. The ligand is rendered as stick and the amino acids of the active site of AChE is presented as wireframe. Water molecules provided as red core

(C₅-Piperazine), 53.1 (Phthalimide-C-C-Piperazine), 54.5 (C_{2,6}-Piperazine), 57.1 (-OCH₃), 114.2 (C_{3,5}-4-Methoxyphenyl), 123.6 (C_{4,7}-4-Phthalimide), 127.8 (C_{2,6}-4-Methoxyphenyl), 128.2 (C₁-4-Methoxyphenyl), 132.1 (C_{3a,7a}-Phthalimide), 135.9 (C_{5,6}-4-Phthalimide), 156.9 (C₄-4-Methoxyphenyl), 167.1 (C=O, Phthalimide), 169.1 (C=O, 4-Methoxybenzoyl). IR (KBr, cm⁻¹) $\bar{\nu}$: 3080 (C-H, Stretch, Aromatic), 2924 (C-H, Stretch, Asymmetric, Aliphatic), 2858 (C-H, Stretch, Symmetric, Aliphatic), 1712 (C=O, Stretch, Phthalimide), 1647, 1435, 1253 (C-N, Stretch).

2-(2-(4-(2-Nitrobenzoyl) piperazin-1-yl) ethyl) isoindoline-1,3-dione (**4j**)

^1H NMR (CDCl₃, 400 MHz) δ (ppm): 2.96 (brs, 4H, Piperazine), 3.44 (brs, 4H, Piperazine), 3.78-3.94 (m, 4H, Phthalimide-CH₂-CH₂-Piperazine), 6.93 (m, 2H, 2-Nitrophenyl), 7.43 (m, 1H, 2-Nitrophenyl), 7.75 (m, 2H, H_{5,6}-Phthalimide), 7.86 (m, 2H, H_{4,7}-Phthalimide), 8.01 (m, 1H, 2-Nitrophenyl). ^{13}C NMR (DMSO- d_6 , 62.5 MHz) δ : ^{13}C NMR (DMSO- d_6 , 62.5 MHz) δ : 37.4 (Phthalimide-C-C-Piperazine), 43.2 (C₃-Piperazine), 45.5 (C₅-Piperazine), 53.6 (Phthalimide-C-C-Piperazine), 54.8 (C_{2,6}-Piperazine),

123.7 (C_{4,7}-Phthalimide), 128.6 (C₃-2-Nitrophenyl), 128.9 (C₁-2-Nitrophenyl), 131.1 (C₄-2-Nitrophenyl), 131.7 (C_{3a,7a}-Phthalimide), 132.2 (C₆-2-Nitrophenyl), 133.1 (C₅-2-Nitrophenyl), 135.4 (C_{5,6}-Phthalimide), 140.6 (C₂-2-Nitrophenyl), 166.1 (C=O, Phthalimide), 167.2 (C=O, 2-Nitrobenzoyl). IR (KBr, cm⁻¹) $\bar{\nu}$: 2967 (C-H, Stretch, Asymmetric, Aliphatic), 2927 (C-H, Stretch, Symmetric, Aliphatic), 1712 (C=O, Stretch, Phthalimide), 1650 (C=O, Stretch, Amide), 1608 (C=C, Stretch, Aromatic), 1470 (C=C, Stretch, Aromatic), 1253 (C-N, Stretch).

Docking study

All ligands were docked into the active site of acetylcholinesterase and the binding state and interacted amino acids were compared to donepezil (Figure 4, Figure 5).

Enzymatic assay

All prepared compounds (**4a-4j**) were tested against acetylcholinesterase by Ellman's test and obtained results were listed in Table 2. Observed potencies were compared with donepezil as reference drug.




Figure 5. Superimposition of compound **4e** with structure of donepezil in the active site of AChE

Table 2. Results of anti-acetylcholinesterase activity of compounds **4a-4j** (IC₅₀, μM)

Compound	4a	4b	4c	4d	4e	4f	4g	4h	4i	4j	Donepezil
R	2-Cl	3-Cl	4-Cl	2-F	3-F	4-F	2-OCH ₃	3-OCH ₃	4-OCH ₃	2-NO ₂	-
IC ₅₀ (μM)	333.4	70.2	> 1000	3.6	7.1*	50.6	100.1	1.3	20.3*	140.6	0.41

* IC₅₀ of compounds **4e** and **4i** have been presented in nanomolar (nM) range

Discussion

Chemistry

A new series of isoindoline-1,3-dione (phthalimide) derivatives were synthesized through the treatment of phthalic anhydride and *N*-amnioethylpiperazine in the presence of triethylamine as proton acceptor. Refluxing condition was applied in toluene solvent to achieve compound **3** with a moderate yield (61%). Then, compound **3** was used for preparation of final product **4a-4j**. Final products were synthesized via a carbodiimide coupling process. Namely, appropriate benzoic acid derivative was mixed with *N*-ethyl-*N*-dimethylaminopropyl carbodiimide (EDC) and hydroxybenzotriazole (HOBT) in acetonitrile (CH₃CN) solvent and after 30 min equimolar quantities of compound **3** was added. The reaction mixture was stirred for 24 hr. Spectroscopic methods such as ¹H NMR, IR and Mass were utilized for characterization of intermediate compound **3** as well as final compounds **4a-4j**. Melting point analyser was used to measure the corresponding melting points using open capillary tube and recorded as centigrade degree. Compound **4d** with *ortho* fluorine substituent demonstrated the highest melting point (247 °C), whereas, compounds **4h** and **4i** with methoxy moiety rendered the lowest melting points (127 °C).

Docking

According to the Figure 3, it is obvious that donepezil has three distinct interactions with acetylcholinesterase enzyme. In the other words, Trp 279, Phe 330 and Trp 84 are the most critical amino acids in the active site of AChE. The binding mode of the tested compounds was investigated by docking method using ArgusLab software. According to the obtained results, there is a similar binding mode and interactions between the docked ligands and donepezil into the active site of acetylcholinesterase (Figure 4, Figure 5). According to the Figure 4, the critical amino acids (Trp 279, Phe 330 and Trp 84) are visible surrounding the docked ligand and also with paying attention to the Figure 5, a similar conformation and orientation like donepezil towards the pivotal amino acids is observable for this ligand in overlaid state.

Structure activity relationship

All final compounds **4a-4j** were tested against acetylcholinesterase enzyme and the obtained results were recorded as IC₅₀ in Table 2. Fortunately, the synthesized derivatives demonstrated a remarkable inhibitory activity towards acetylcholinesterase.

Various substituents such as Cl, F, methoxy and nitro were introduced on the phenyl ring to explore the impact of electronic effects of the moiety on the potency of these compounds in inhibition of acetylcholinesterase activity. In the other words, electron withdrawing as well as electron donating moiety were examined. According to the Table 2, it is obvious that both of the electron withdrawing and electron donating moiety have beneficial effect on the potency of the synthesized derivatives. Compound **4e** with *meta* fluorine moiety was the most active compound in this series (IC₅₀ = 7.1 nM). Generally, electron withdrawing groups like chlorine and fluorine at position *meta* of the phenyl ring provided a better activity compared to positioning of these moieties at *ortho* and *para*. Positioning of the methoxy at *para* (compound **4i**, IC₅₀ = 20.3 nM) also rendered a favorable potency but lower than compound **4e**. Compounds **4d** and **4h** were also exhibited an acceptable activity in μM range but lower than donepezil. It means that methoxy as an electron donating moiety at position *meta* could also enhance the anticholinesterase activity in comparison with *ortho* position. *Ortho* positioning of chlorine and nitro moieties did not caused a significant increase in activity. It is probable that steric effect that caused by chlorine and nitro moiety be an interrupting factor for proper interaction of these ligands with receptor at position *ortho*.

Totally, electron withdrawing atoms enhanced the anticholinesterase activity especially at position 3 of the phenyl ring. Increase in electron withdrawing effects was also beneficial for activity. In the other words, replacement of the chlorine with fluorine atom led to the improvement in activity in all positions of the phenyl ring. Electron donating groups is better to substitute at position 3 and 4 of the phenyl ring.

Conclusion

A new series of phthalimide (isoindoline-1,3-dione) derivatives were synthesized and corresponding anti-acetylcholinesterase activity were assessed using Ellman protocol. Molecular docking was also carried out for exploration of the probable binding mode of the ligands and also for comparison with donepezil. Totally, electron withdrawing groups (Cl, F) at position 3 and electron donating group (methoxy) at position 4 of the phenyl ring enhanced the activity. Compound **4e** (*m*-Fluoro, IC₅₀ = 7.1 nM) and **4i** (*p*-Methoxy, IC₅₀ = 20.3 nM) were the most active compounds in this series and exerted superior potency than donepezil (410 nM). Molecular modeling by docking method also confirmed

the results of enzymatic test. Moreover, a similar binding mode was observed for all ligands in superimposition state with donepezil into the active site of acetylcholinesterase.

Acknowledgment

Authors appreciate from the Research Council of Kermanshah University of Medical Sciences for financial supports. This work was performed in partial fulfillment of the requirement for PharmD of Mrs Nasibeh Abdi.

References

1. Sugimoto H, Yamanishi Y, Iimura Y, Kawakami Y. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. *Curr Med Chem* 2000; 7:303-339.
2. Zhang J, Zhu D, Sheng R, Wu H, Hu Y, Wang F, et al. BZYX, a novel acetylcholinesterase inhibitor, significantly improved chemicals-induced learning and memory impairments on rodents and protected PC12 cells from apoptosis induced by hydrogen peroxide. *Eur J Pharmacol* 2009; 613:1-9.
3. Ucar G, Gokhan N, Yesilada A, Bilgin AA. 1-*N*-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: A novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases. *Neurosci Lett* 2005; 382:327-331.
4. Liston DR, Nielsen JA, Villalobos A, Chapin D, Jones SB, Hubbard ST, et al. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease. *Eur J Pharmacol* 2004; 486:9-17.
5. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. *Lancet Neurol* 2003; 2:539-547.
6. Vitorović-Todorović MD, Juranić IO, Mandić LM, Drakulic BJ. 4-Aryl-4-oxo-*N*-phenyl-2-aminylbutyramides as acetyl- and butyrylcholinesterase inhibitors. Preparation, anticholinesterase activity, docking study, and 3D structure-activity relationship based on molecular interaction fields. *Bioorg Med Chem* 2010; 18:1181-1193.
7. Kapková P, Alptüzün V, Frey P, Erciyasb E, Holzgrabe U. Search for dual function inhibitors for Alzheimer's disease: Synthesis and biological activity of acetylcholinesterase inhibitors of pyridinium-type and their A β fibril formation inhibition capacity. *Bioorg Med Chem* 2006; 14:472-478.
8. Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K. Synthesis and Structure-Activity Relationships of Acetylcholinesterase Inhibitors: 1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine Hydrochloride and Related Compounds. *J Med Chem* 1995; 24:4821-4829.
9. Foroumadi A, Mohammadi-Farani A, Garmsiri Mahvar M, Aliabadi A. Synthesis and evaluation of anti-acetylcholinesterase activity of 2-(2-(4-(2-Oxo-2-phenylethyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione derivatives with potential anti-Alzheimer effects. *Iran J Basic Med Sci* 2013; 10:1049-1054.
10. Mohammadi-Farani A, Ahmadi A, Nadri H, Aliabadi A. Synthesis, docking and acetylcholinesterase inhibitory assessment of 2-(2-(4-Benzylpiperazin-1-yl)ethyl)isoindoline-1,3-dione with potential anti-alzheimer effects. *Daru* 2013; 21:47-55.
11. Zhao Q, Yang G, Mei X, Yuan H, Ning J. Novel acetylcholinesterase inhibitors: Synthesis and structure-activity relationships of phthalimide alkyloxyphenyl *N,N*-dimethylcarbamate derivatives. *Pestic Biochem Physiol* 2009; 95:131-134.
12. Kryger G, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with E2020 (Aricept®): implications for the design of new anti-Alzheimer drugs. *Structure* 1999; 3:297-307.
13. Alonso D, Dorronsoro I, Rubio L, Munoz P, García-Palomero E, Del Monte M, et al. Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. *Bioorg Med Chem* 2005; 13:6588-6597.
14. Mary A, Zafiarisoa Renko D, Guillou C, Thal C. Potent acetylcholinesterase inhibitors: design, synthesis, and structure-activity relationships of bis-interacting ligands in the galanthamine series. *Bioorg Med Chem* 1998; 6:1835-1850.
15. Ragavendran JV, Sriram D, Patel SK, Reddy IV, Bharathwajan N, Stables J. Design and synthesis of anticonvulsants from a combined phthalimide-GABA-anilide and hydrazone pharmacophore. *Eur J Med Chem* 2007; 42:146-151.
16. Mohammadi-Farani A, Foroumadi A, Rezvani Kashani M, Aliabadi A. *N*-Phenyl-2-*p*-tolylthiazole-4-carboxamide derivatives: Synthesis and cytotoxicity evaluation as anticancer agents. *Iran J Basic Med Sci* 2014; 17:502-508.
17. Mohammadi-Farani A, Heidarian N, Aliabadi A. *N*-(5-Mercapto-1,3,4-thiadiazol-2-yl)-2-phenylacetamide derivatives: Synthesis and *in vitro* cytotoxicity evaluation as potential anticancer agents. *Iran J Pharm Res* 2014; 12:487-492.
18. Aliabadi A, Foroumadi A, Safavi M, Kaboudian Ardestani S. Synthesis, molecular docking and cytotoxicity evaluation of 2-(4-substituted-benzyl)isoindoline-1,3-dione derivatives as anticancer agents. *J Rep Pharm Sci* 2012; 1:19-22.
19. Aliabadi A, Shamsa F, Ostad SN, Emami S, Shafiee A, Davoodi J, et al. Synthesis and biological evaluation of 2-Phenylthiazole-4-carboxamide derivatives as anticancer agents. *Eur J Med Chem* 2010; 11:5384-5389.
20. ArgusLab 4.0 Mark A. Thompson Planaria Software LLC, Seattle, WA. <http://www.arguslab.com/arguslab.com/ArgusLab.html>.
21. <http://RCSB.org>.
22. Fernandez D, Aviles FX, Vendrell J. A new type of five-membered heterocyclic inhibitors of basic metalloproteases. *Eur J Med Chem* 2009; 44:3266-3271.
23. <http://www.molegro.com>.
24. Ellman GL, Courtney KD, Andres V, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol* 1961; 7:88-95.
25. Nadri H, Piralı-Hamedani M, Shekarchi M, Abdollahi M, Sheibani V, Amanlou M, et al. Design, synthesis and anticholinesterase activity of a novel series of 1-benzyl-4-((6-alkoxy-3-oxobenzofuran-2(3H)-ylidene)methyl)pyridinium derivatives. *Bioorg Med Chem* 2010; 18:6360-6366.